Halozyme Therapeutics, Inc. Detailed Financials

Full historical quarterly statements

Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue376.7M451.8M354.3M325.7M264.9M298.0M290.1M231.4M
Cost of Goods Sold108.8M102.1M73.0M64.1M66.2M42.1M49.4M57.4M
Gross Profit268.0M349.6M281.3M261.6M198.7M256.0M240.7M174.0M
R&D Expenses25.6M31.9M17.3M17.5M14.8M20.4M18.5M21.0M
Operating Expenses83.4M95.2M63.3M59.2M57.2M80.5M77.5M56.7M
Operating Income184.5M254.4M217.9M202.4M141.5M175.5M163.2M117.2M
Other Income / Gains-4.2M-355.2M1.0M2.5M2.3M2.7M1.9M508K
Net Income150.0M-141.6M175.2M165.2M118.1M137.0M137.0M93.2M
EPS (Diluted)1.27-1.201.491.360.961.081.080.73
Reported CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Gross Profit Ratio0.7110.7740.7940.8030.750.8590.830.752
General And Administrative Expenses00000000
Selling And Marketing Expenses00000000
Selling General And Administrative Expenses57.9M63.3M46.1M41.6M42.4M42.2M41.2M35.7M
Other Expenses0000017.8M17.8M0
Cost And Expenses192.2M197.4M136.3M123.3M123.3M122.5M126.9M114.1M
Interest Income1.3M05.3M6.9M0000
Interest Expense5.5M4.9M4.3M4.4M4.5M4.5M4.5M4.5M
Depreciation And Amortization33.7M26.7M20.5M20.5M20.4M20.4M20.4M20.4M
Ebitda218.3M281.1M238.4M222.9M162.0M203.2M190.0M137.6M
Ebitdaratio0.5790.6220.6730.6840.6120.6820.6550.595
Operating Income Ratio0.490.5630.6150.6220.5340.5890.5630.507
Income Before Tax180.3M-100.8M219.0M204.9M143.8M178.2M165.1M117.7M
Income Before Tax Ratio0.479-0.2230.6180.6290.5430.5980.5690.509
Income Tax Expense30.3M40.7M43.7M39.8M25.7M41.2M28.1M24.5M
Net Income Ratio0.398-0.3130.4950.5070.4460.460.4720.403
Epsdiluted1.22-1.201.431.330.931.061.050.72
Weighted Average Shs Out118.1M117.7M117.2M121.3M123.2M126.4M126.8M127.1M
Weighted Average Shs Out Dil122.9M117.7M122.3M124.2M126.6M129.4M130.1M129.2M